Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy

BACKGROUND: Trifluridine/tipiracil is an oral agent approved for the treatment of patients with metastatic colorectal cancer (mCRC). Trifluridine is an antineoplastic thymidine analogue, and tipiracil improves its bioavailability. A phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Takayuki, Oki, Eiji, Nozawa, Hiroaki, Eguchi-Nakajima, Takako, Taniguchi, Hiroya, Morita, Satoshi, Takenaka, Naruhito, Ozawa, Daisuke, Shirao, Kuniaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109822/
https://www.ncbi.nlm.nih.gov/pubmed/30167332
http://dx.doi.org/10.1136/esmoopen-2018-000411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109822/
https://www.ncbi.nlm.nih.gov/pubmed/30167332
http://dx.doi.org/10.1136/esmoopen-2018-000411

Ejemplares similares